Bone Marrow Transplantation News

NEW ORLEANS — The location of a subset of hematopoietic stem cells in the vicinity of megakaryocytes is nonrandom, according to study findings presented at the ASH Annual Meeting and Exposition.

Autologous stem cell transplantation significantly improved outcomes in patients with Philadelphia-positive acute lymphoblastic leukemia, according to study results.

NEW ORLEANS — Removing alpha- and beta-positive T cells and CD19-postive B cells from the donor graft reduced the risk for graft-versus-host disease and transplant-related mortality in children with acute leukemia undergoing HLA-haploidentical hematopoietic stem cell transplantation, according to study results presented at the ASH Annual Meeting and Exposition.

NEW ORLEANS — Reduced-intensity, related haploidentical blood or marrow transplantation followed by high-dose cyclophosphamide does not carry prohibitive toxicities in older patients, according to a study presented at the ASH Annual Meeting and Exposition.

NEW ORLEANS — The infusion of donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells caused regression of highly treatment-resistant B-cell malignancies after allogeneic hematopoietic stem cell transplantation, according to study results presented at the ASH Annual Meeting and Exposition.

Patients who received hematopoietic stem cell transplantation as part of childhood cancer treatment exhibited an increased risk of developing kidney stones as adults, according to results of a retrospective study.

A young age at hematopoietic stem cell transplantation represented a significant risk factor for bone deficits in early adulthood, according to study results.

Cleveland Clinic recently appointed two physicians to leadership positions.

The desire to detect minimal residual disease in patients with cancer as a way to predict prognosis or relapse risk became a reality in the past decade due to the development of technology sensitive enough to measure minute levels of cancerous cells in human tissue.

Zoledronic acid should remain the preferred treatment for patients with newly diagnosed multiple myeloma who undergo autologous stem cell transplantation, results of a retrospective study suggest.